time
pandem
question
aris
regard
patient
treat
immunomodulatori
therapi
particular
increas
risk
acquir
infect
experienc
wors
outcom
exact
question
present
unanswer
look
safeti
data
clinic
trial
tri
understand
patient
suscept
differ
infect
other
address
context
biolog
classic
small
molecul
therapi
risk
janu
kinas
inhibitor
jaki
treatment
address
light
grow
offlabel
use
jaki
dermatolog
addit
pharmaceut
industri
sponsor
clinic
trial
jaki
alopecia
areata
atop
dermat
vitiligo
etc
dermatologist
need
data
better
understand
risk
jaki
treatment
order
best
manag
counsel
patient
uniqu
time
analyz
collat
advers
event
data
jaki
clinic
trial
particular
focus
infect
pulmonari
toxic
observ
across
differ
fdaapprov
jaki
approv
indic
avail
data
phase
ii
iii
clinic
trial
dermatolog
indic
includ
tabl
show
rate
variou
infect
includ
upper
respiratori
infect
nasopharyng
influenza
jakitr
group
versu
placebo
group
overal
rate
infecti
event
mildli
increas
jakitr
patient
also
collat
pulmonari
toxic
jaki
identifi
potenti
risk
worsen
sever
respiratori
diseas
toxic
absent
order
understand
infect
data
help
understand
mechan
pharmacokinet
jaki
cytokin
drive
autoimmun
activ
exagger
figur
jaki
taken
oral
time
per
day
larg
impact
pathogen
elev
cytokin
activ
rel
spare
normal
cytokin
activ
drug
concentr
therapeut
part
day
figur
time
pandem
must
inform
possibl
regard
risk
treatment
prescrib
patient
cours
share
decisionmak
reign
suprem
without
data
physician
unabl
provid
patient
guidanc
reli
us
